Moneycontrol PRO
abbott india
Jump to
18 Results Found
  • 634 drugs on NPPA's price ceiling non-compliant list Feb 23, 2017 09:10 PM IST

    634 drugs on NPPA's price ceiling non-compliant list

    As many as 634 drugs of various strengths produced by firms, including Cipla, Abbott, Astrazeneca and Dr Reddy's, are "suspected" to be non-compliant with ceiling prices as notified by NPPA.

  • Stocks in news: Axis, Tata Motors, Sun Pharma, IRB, Fortis, MEP Dec 13, 2016 08:01 AM IST

    Stocks in news: Axis, Tata Motors, Sun Pharma, IRB, Fortis, MEP

    Axis Bank | Tata Motors | Sun Pharma | IRB Infrastructure | Sunteck Realty | NIIT | Fortis Healthcare | Abbot India | APL Apollo Tubes | Aarey Drugs | PAE | MEP Infra and Bajaj Finance are stocks, which are in the news today.

  • Stocks in news: Cipla, GAIL, Tata Elxsi, Aurobindo, Ricoh, Uflex Nov 28, 2016 08:01 AM IST

    Stocks in news: Cipla, GAIL, Tata Elxsi, Aurobindo, Ricoh, Uflex

    Bharti Airtel | Cipla | GAIL | Idea Cellular | Apollo Tyres | Tata Elxsi | Aurobindo Pharma | Uflex | Dilip Buildcon | ARSS Infra | GPT Infra | Strides Shasun | Ashok Leyland and Ricoh India are stocks, which are in the news today.

  • FDC ban not done in proper manner; large brands to suffer: Pros Mar 17, 2016 10:45 AM IST

    FDC ban not done in proper manner; large brands to suffer: Pros

    Kewal Handa, industry expert and former MD of Pfizer says that alongwith sales loss, companies will also have to bear brunt of inventory loss as the decision has been immediate.

  • Stocks that are likely to be in focus in today's trade Mar 17, 2016 08:31 AM IST

    Stocks that are likely to be in focus in today's trade

    Here are the stocks that are likely to be in focus in today's trade

  • Delhi HC stays ban on 344 drugs; interim relief for pharma cos Mar 15, 2016 07:46 PM IST

    Delhi HC stays ban on 344 drugs; interim relief for pharma cos

    The Delhi HC has asked the government to explain its position and actions of issuing the March 10 notification. It has also stayed the notification with respect to Abbott and MacLeod and the stay will be in operation until next hearing on March 21.

  • Aim is to prevent rampant use of antibiotics: P Lilladher Mar 14, 2016 09:18 AM IST

    Aim is to prevent rampant use of antibiotics: P Lilladher

    Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.

  • Here's why pharma, telecom and bank stocks are in focus Mar 14, 2016 08:44 AM IST

    Here's why pharma, telecom and bank stocks are in focus

    Pharma companies such as Pfizer, Abbott, Glenmark and Wockhardt are likely to be in focus with the government banning over 300 drugs

  • Dr Reddy's Labs top pick, says Mehraboon Irani Oct 13, 2015 04:36 PM IST

    Dr Reddy's Labs top pick, says Mehraboon Irani

    Mehraboon Irani of Nirmal Bang Securities is of the view that Dr Reddy's Labs is the top pick.

  • Godrej Prop sells its BKC project for Rs 1,479cr to Abbott Sep 30, 2015 12:04 PM IST

    Godrej Prop sells its BKC project for Rs 1,479cr to Abbott

    The project was being developed for Jet Airways on a 50:50 profit-sharing agreement.

  • Godrej Prop to monetise BKC project; reduce debt: Sources Sep 16, 2015 12:28 PM IST

    Godrej Prop to monetise BKC project; reduce debt: Sources

    Godrej Properties is developing the BKC project for Jet Airways on a 50:50 sharing agreement.

  • Positively biased in Dr Reddy's Labs: Mehraboon Irani Jul 30, 2015 04:43 PM IST

    Positively biased in Dr Reddy's Labs: Mehraboon Irani

    Mehraboon Irani of Nirmal Bang Securities is positively biased in Dr Reddy's Laboratories.

  • What took mighty Lupin down! Jul 24, 2015 03:46 PM IST

    What took mighty Lupin down!

    In an interview with CNBC-TV18‘s Sonia Shenoy & Latha Venkatesh, Praful Bohra, VP- Research, Religare said that Lupin‘s numbers are weak due to decline in the US business.

  • Market maintains bull run, experts remain bullish Nov 24, 2014 04:29 PM IST

    Market maintains bull run, experts remain bullish

    Market expert Ambareesh Baliga believes market will move up over the next four-five days or one week. According to him, the appetite for such market is quite high as investors and traders are making a lot of money now.

  • Pick Abbott India on correction: Vishal Jajoo Aug 22, 2014 10:55 AM IST

    Pick Abbott India on correction: Vishal Jajoo

    Vishal Jajoo, of Nirmal Bang Commodities is of the view that one can buy Abbott India on correction.

  • See IT, pharma outperforming; optimistic on market: Damani Jan 03, 2014 10:53 AM IST

    See IT, pharma outperforming; optimistic on market: Damani

    Ramesh Damani, member, BSE said the undertone of the market was quite strong, and there was every reason to be optimistic.

  • Accumulate Abbott India, says Aashish Tater Jul 30, 2012 10:32 AM IST

    Accumulate Abbott India, says Aashish Tater

    Accumulate Abbott India, says Aashish Tater, Head of Research, Fort Share Broking.

  • Abbott India looks good: Shanbhag Jun 10, 2011 05:22 PM IST

    Abbott India looks good: Shanbhag

    Abbott India looks good, says Ganesh Shanbhag, CEO, SMS Financial Services.

Sections
ISO 27001 - BSI Assurance Mark